AU2020258729A1 - Lipoic acid prodrug - Google Patents

Lipoic acid prodrug Download PDF

Info

Publication number
AU2020258729A1
AU2020258729A1 AU2020258729A AU2020258729A AU2020258729A1 AU 2020258729 A1 AU2020258729 A1 AU 2020258729A1 AU 2020258729 A AU2020258729 A AU 2020258729A AU 2020258729 A AU2020258729 A AU 2020258729A AU 2020258729 A1 AU2020258729 A1 AU 2020258729A1
Authority
AU
Australia
Prior art keywords
different
same
compound
substituted
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020258729A
Other languages
English (en)
Inventor
Tatsuya Hata
Takahiro Honda
Masatomo Kato
Tomoko Oda
Shinji Takaoka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Santen Pharmaceutical Co Ltd
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of AU2020258729A1 publication Critical patent/AU2020258729A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/02—Five-membered rings
    • C07D339/04—Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2020258729A 2019-04-17 2020-04-16 Lipoic acid prodrug Abandoned AU2020258729A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019-078798 2019-04-17
JP2019078798 2019-04-17
PCT/JP2020/016774 WO2020213693A1 (ja) 2019-04-17 2020-04-16 リポ酸プロドラッグ

Publications (1)

Publication Number Publication Date
AU2020258729A1 true AU2020258729A1 (en) 2021-11-11

Family

ID=72837203

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020258729A Abandoned AU2020258729A1 (en) 2019-04-17 2020-04-16 Lipoic acid prodrug

Country Status (9)

Country Link
US (1) US20220151989A1 (cg-RX-API-DMAC7.html)
EP (1) EP3957365A4 (cg-RX-API-DMAC7.html)
JP (1) JPWO2020213693A1 (cg-RX-API-DMAC7.html)
KR (1) KR20220002965A (cg-RX-API-DMAC7.html)
CN (1) CN113710320A (cg-RX-API-DMAC7.html)
AU (1) AU2020258729A1 (cg-RX-API-DMAC7.html)
CA (1) CA3136938A1 (cg-RX-API-DMAC7.html)
TW (1) TW202103696A (cg-RX-API-DMAC7.html)
WO (1) WO2020213693A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202305212D0 (en) * 2023-04-06 2023-05-24 Elixa Mediscience Ltd Compounds
CN117263907B (zh) * 2023-09-23 2026-01-27 江西科技师范大学 一种丙酮酸脱氢酶e2抑制剂及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11269170A (ja) * 1997-04-02 1999-10-05 Sankyo Co Ltd ジチオラン誘導体
CZ96798A3 (cs) * 1997-04-02 1998-10-14 Sankyo Company Limited Deriváty dithiolanu, jejich příprava a jejich terapeutické účinky
US8697109B2 (en) * 2000-08-16 2014-04-15 Encore Health, Llc Caged mercaptan and seleno-mercaptan compounds and methods of using them
US9044439B2 (en) * 2008-03-05 2015-06-02 Encore Health, Llc Low dose lipoic and pharmaceutical compositions and methods
EP3069612A3 (en) * 2009-06-15 2016-10-19 Encore Health, LLC Dithiol compounds, derivatives, and uses therefor
WO2010147962A1 (en) * 2009-06-15 2010-12-23 Encore Health, Llc Choline esters
CA2941518A1 (en) * 2014-03-03 2015-09-11 Encore Vision, Inc. Lipoic acid choline ester compositions and methods of use

Also Published As

Publication number Publication date
US20220151989A1 (en) 2022-05-19
EP3957365A4 (en) 2023-01-11
TW202103696A (zh) 2021-02-01
KR20220002965A (ko) 2022-01-07
CA3136938A1 (en) 2020-10-22
EP3957365A1 (en) 2022-02-23
JPWO2020213693A1 (cg-RX-API-DMAC7.html) 2020-10-22
WO2020213693A1 (ja) 2020-10-22
CN113710320A (zh) 2021-11-26

Similar Documents

Publication Publication Date Title
US11185538B2 (en) Compositions for treating glaucoma or reducing intraocular pressure
JP2011510965A (ja) 高眼圧症の治療のためのジフルオロビフェニルアミド誘導体
RU2577546C2 (ru) 7-[3,5-дигидрокси-2-(3-гидрокси-5-фенил-пент-1-енил)-циклопентил]-n-этил-гепт-5-енамид (биматопрост) в кристаллической форме ii, способы его получения и способы его применения
EP3900714A1 (en) Agent containing 4-phenylbutyrate, for preventing or treating presbyopia
AU2020258729A1 (en) Lipoic acid prodrug
CA3214066A1 (en) 1,3-substituted cyclobutyl derivatives and uses thereof
JP2010514733A (ja) 高眼圧症の治療のためのイソソルビドモノニトレート誘導体
ES2844531T3 (es) Formas cristalinas de ácido bimatoprost, métodos para la preparación y métodos para el uso de las mismas
JPH0427976B2 (cg-RX-API-DMAC7.html)
JP2025514548A (ja) カレバスチンの塩及びその用途
JP2016056207A (ja) プロスタグランジンアゴニストのプロドラッグの安定した水性組成物およびその使用方法
WO2021113808A1 (en) Cftr-modulating arylamides
JPH02138252A (ja) ５‐置換１‐〔４‐（１‐ピロリジニル）‐２‐ブチニル〕‐２‐ピロリドン類および類似化合物
ES2717481T3 (es) Engrosamiento corneal central reducido mediante el uso de profármacos de ésteres hidrófilos de beta-clorociclopentanos
EP4159209A1 (en) Sulfur-containing compound useful for treating or preventing presbyopia
EP3187179A1 (en) Pharmaceutical composition for prophylaxis and/or treatment of corneal and conjunctival diseases or presbyopia containing stilbene compound as active ingredient
WO2023058673A1 (ja) 老視等の治療または予防に有用な含硫黄化合物
JP2025502536A (ja) Ｍ－コリン受容体アゴニスト化合物及びその製造方法並びに使用
CN121270500A (zh) 含一氧化氮供体的黄酮类衍生物
BR112023019496B1 (pt) Derivados de ciclobutila 1,3-substituída, e composição farmacêutica
EA050893B1 (ru) Производные 1,3-замещенного циклобутила и способы их применения
MXPA99008203A (en) 13-thia prostaglandins for use in glaucoma therapy

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period